Independent
Tenure on this board
17.3 yrs
Also a director at
Kforce Inc (KFRC)
10 nominees · 5 ballot items.
Election of 10 directors; Ratification of PwC as independent auditors; Advisory (say-on-pay) vote to approve 2025 NEO compensation; Approval to amend 2017 long term equity incentive plan to add 480,000 shares; Stockholder proposal by John Chevedden on shareholder right to act by written consent.
Elect ten directors named in the proxy to serve until the 2027 Annual Meeting.
Ratify PricewaterhouseCoopers LLP as Assurant’s independent registered public accounting firm for fiscal year 2026.
Non-binding advisory vote (say-on-pay) to approve the Company’s 2025 NEO compensation disclosed in the proxy.
Approve an amendment to the 2017 long term equity incentive plan to increase the share reserve by 480,000 common shares.
Stockholder proposal requesting the Board to permit shareholder action by written consent without unnecessary restrictions and allow shareholders to initiate topics for written consent.
The proponent, John Chevedden, requests the Board to enable shareholder action by written consent by shareholders holding the minimum votes required to authorize actions at a fully-attended meeting, arguing Assurant’s 25% special meeting threshold is too high and written consent would provide a timely mechanism to address underperformance and governance concerns. Management opposes on governance and practical grounds, pointing to the adoption of a 25% special meeting right, robust engagement, and risks that written consents could disenfranchise other shareholders or enable minority agendas; management also cites prevailing S&P 500 practice of not permitting written consent or requiring unanimity. Company-specific context includes recent operational and financial challenges in 2025 (catastrophes, investment income, FX headwinds) that the proponent cites as justification for the change, while the Board emphasizes its prior engagement and adjustments like the special meeting right as balancing stockholder access and governance stability.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 6.60% | 3,272,043 | $713M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 6.55% | 3,243,504 | $706M |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 6.07% | 3,008,137 | $655M |
| 4 | STATE STREET CORP | 5.11% | 2,531,416 | $551M |
| 5 | Bank of New York Mellon Corp | 3.59% | 1,776,747 | $387M |
| 6 | Bank of New York Mellon Corp | 3.41% | 1,688,473 | $368M |
| 7 | BlackRock, Inc. | 3.24% | 1,603,282 | $349M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.51% | 1,243,604 | $270M |
| 9 | BlackRock, Inc. | 2.23% | 1,105,428 | $241M |
| 10 | PRICE T ROWE ASSOCIATES INC /MD/ | 2.16% | 1,072,019 | $233M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.